Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

2.

The STAMPEDE trial: paradigm-changing data through innovative trial design.

Carthon BC, Antonarakis ES.

Transl Cancer Res. 2016 Sep;5(3 Suppl):S485-S490.

3.

Oncological outcomes following radical prostatectomy for patients with pT4 prostate cancer.

Kaushik D, Boorjian SA, Thompson RH, Eisenberg MS, Carlson RE, Bergstralh EJ, Frank I, Gettman MT, Tollefson MK, Karnes RJ.

Int Braz J Urol. 2016 Nov-Dec;42(6):1091-1098. doi: 10.1590/S1677-5538.IBJU.2016.0290.

4.

Prospective assessment of the quality of life before, during and after image guided intensity modulated radiotherapy for prostate cancer.

Sveistrup J, Mortensen OS, Bjørner JB, Engelholm SA, Munck Af Rosenschöld P, Petersen PM.

Radiat Oncol. 2016 Sep 7;11(1):117. doi: 10.1186/s13014-016-0689-4.

5.

PSA nadir as a predictive factor for biochemical disease-free survival and overall survival following whole-gland salvage HIFU following radiotherapy failure.

Shah TT, Peters M, Kanthabalan A, McCartan N, Fatola Y, van der Voort van Zyp J, van Vulpen M, Freeman A, Moore CM, Arya M, Emberton M, Ahmed HU.

Prostate Cancer Prostatic Dis. 2016 Sep;19(3):311-6. doi: 10.1038/pcan.2016.23.

PMID:
27431499
6.

Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy.

Pham T, Sadowski MC, Li H, Richard DJ, d'Emden MC, Richard K.

Exp Hematol Oncol. 2016 Jun 22;5:15. doi: 10.1186/s40164-016-0046-1. Review.

7.

Evolving Paradigm of Radiotherapy for High-Risk Prostate Cancer: Current Consensus and Continuing Controversies.

Juloori A, Shah C, Stephans K, Vassil A, Tendulkar R.

Prostate Cancer. 2016;2016:2420786. doi: 10.1155/2016/2420786. Review.

8.

Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.

Botrel TE, Clark O, Lima Pompeo AC, Horta Bretas FF, Sadi MV, Ferreira U, Borges Dos Reis R.

PLoS One. 2016 Jun 16;11(6):e0157660. doi: 10.1371/journal.pone.0157660.

9.

Diagnosis, referral, and primary treatment decisions in newly diagnosed prostate cancer patients in a multidisciplinary diagnostic assessment program.

Guy D, Ghanem G, Loblaw A, Buckley R, Persaud B, Cheung P, Chung H, Danjoux C, Morton G, Noakes J, Spevack L, Hajek D, Flax S.

Can Urol Assoc J. 2016 Mar-Apr;10(3-4):120-5. doi: 10.5489/cuaj.3510.

10.

Radiotherapy and Hormone Treatment in Prostate Cancer.

Böhmer D, Wirth M, Miller K, Budach V, Heidenreich A, Wiegel T.

Dtsch Arztebl Int. 2016 Apr 8;113(14):235-41. doi: 10.3238/arztebl.2016.0235.

11.

PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges.

Rowe SP, Gorin MA, Allaf ME, Pienta KJ, Tran PT, Pomper MG, Ross AE, Cho SY.

Prostate Cancer Prostatic Dis. 2016 Sep;19(3):223-30. doi: 10.1038/pcan.2016.13. Review.

12.

Pelvic Radiotherapy versus Radical Prostatectomy with Limited Lymph Node Sampling for High-Grade Prostate Adenocarcinoma.

Baker CB, McDonald AM, Yang ES, Jacob R, Rais-Bahrami S, Nix JW, Fiveash JB.

Prostate Cancer. 2016;2016:2674954. doi: 10.1155/2016/2674954.

13.
14.

Androgen Deprivation Followed by Acute Androgen Stimulation Selectively Sensitizes AR-Positive Prostate Cancer Cells to Ionizing Radiation.

Hedayati M, Haffner MC, Coulter JB, Raval RR, Zhang Y, Zhou H, Mian O, Knight EJ, Razavi N, Dalrymple S, Isaacs JT, Santos A, Hales R, Nelson WG, Yegnasubramanian S, DeWeese TL.

Clin Cancer Res. 2016 Jul 1;22(13):3310-9. doi: 10.1158/1078-0432.CCR-15-1147.

PMID:
26831716
15.

Current clinical challenges in prostate cancer.

Silberstein JL, Pal SK, Lewis B, Sartor O.

Transl Androl Urol. 2013 Sep;2(3):122-36. doi: 10.3978/j.issn.2223-4683.2013.09.03. Review.

16.

Role of hormonal therapy for prostate cancer: perspective from Japanese experiences.

Namiki M, Ueno S, Kitagawa Y.

Transl Androl Urol. 2012 Sep;1(3):160-72. doi: 10.3978/j.issn.2223-4683.2012.07.03. Review.

17.

Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.

Vale CL, Burdett S, Rydzewska LH, Albiges L, Clarke NW, Fisher D, Fizazi K, Gravis G, James ND, Mason MD, Parmar MK, Sweeney CJ, Sydes MR, Tombal B, Tierney JF; STOpCaP Steering Group..

Lancet Oncol. 2016 Feb;17(2):243-56. doi: 10.1016/S1470-2045(15)00489-1. Review. Erratum in: Lancet Oncol. 2016 Feb;17(2):e46.

18.

Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer.

Wu C, Jin X, Yang J, Yang Y, He Y, Ding L, Pan Y, Chen S, Jiang J, Huang H.

Oncotarget. 2016 Jan 19;7(3):3440-52. doi: 10.18632/oncotarget.6497.

19.

A prospective study of nomogram-based adaptation of prostate radiotherapy target volumes.

Wu R, Woodford H, Capp A, Hunter P, Cowin G, Tai KH, Nguyen PL, Chong P, Martin J.

Radiat Oncol. 2015 Nov 25;10:243. doi: 10.1186/s13014-015-0545-y.

20.

Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial.

James ND, Spears MR, Clarke NW, Dearnaley DP, Mason MD, Parker CC, Ritchie AW, Russell JM, Schiavone F, Attard G, de Bono JS, Birtle A, Engeler DS, Elliott T, Matheson D, O'Sullivan J, Pudney D, Srihari N, Wallace J, Barber J, Syndikus I, Parmar MK, Sydes MR; STAMPEDE Investigators..

JAMA Oncol. 2016 Mar;2(3):348-57. doi: 10.1001/jamaoncol.2015.4350. Erratum in: JAMA Oncol. 2016 Feb;2(2):279.

Items per page

Supplemental Content

Support Center